There are many challenges that face companies taking a NCE into early stage feasibility testing and beyond. Some of these challenges are specific to the physical and chemical properties of the molecule in question (e.g. hard to handle API) whilst other challenges are related to the embryonic stage of development that these molecules are in. … Read more
29th October 2019 – Press Release Upperton Pharma Solutions, a UK-based contract development and manufacturing organisation (CDMO) has significantly increased its solid dosage form capabilities following a strategic investment in a new state-of the-art tablet coater. This investment will enhance the company’s development and manufacturing capabilities whilst strengthening their ability to support clients’ research, development … Read more
There are many challenges that face companies taking an NCE into early stage feasibility testing and beyond. Some of these challenges are specific to the physical and chemical properties of the molecule in question whilst other challenges are related to the embryonic stage of development that these molecules are in (e.g. limited API). When early stage … Read more
17th September 2019 – Press Release In recent weeks Upperton has been focussing heavily on enhancing our formulation capabilities (through increased tabletting capabilities) with a series of investments in new equipment for our R&D and QC laboratories. This is now being followed by our largest ever capital investment programme aimed at bringing in new manufacturing … Read more
The start of September is always a busy time in anyone’s calendar, whether you are a parent getting your children ready for school or a small CDMO looking to ramp up your development activities after the summer slowdown. Here at Upperton things are no different, September marks the start of what is traditionally one of … Read more
Upperton celebrated their 20th anniversary on the 31st August and to mark the occasion we are releasing a two-part newsletter. Last week Upperton’s Founder and CEO Dr Richard Johnson talked about the company’s origins, what has driven the business success and how the industry has changed. In this week’s edition Richard Johnson looks forward and … Read more
Celebrating 20 years of pharmaceutical spray drying Upperton will be celebrating its 20th anniversary on the 31st August 2019. Over this time Upperton has developed from a small consultancy business to become one of the world’s leading exponents of pharmaceutical spray drying services. To mark this occasion, we are publishing a special two-part newsletter. In … Read more
Dosage Form Selection Designing a Process for Tablet Manufacture Designing a Process for Capsule Manufacture FAQs Dosage Form Selection Producing a spray dried powder is rarely the end of developing an oral dosage form pathway. Further processing is usually required in order to create a oral dosage form that can be administered in First-in-Human (FIH) … Read more
Upperton Pharma Solutions are one of the very few CDMO’s that have a bespoke, fully equipped non-GMP pilot plant designed to reduce the timelines and the costs for scale up and transfer of spray drying processes into GMP manufacturing. Spray Drying Development and Scale up Formulation and early process development studies are performed in the Upperton … Read more
19th March 2019 – Engineered Powder for Enhanced Pulmonary Delivery Upperton is continuing to invest in its combined spray drying and micronisation technology in order to meet increased demand. This emerging processing technology has been developed to enable the production of larger quantities of engineered powder formulations suitable for pulmonary delivery. The expansion of this service has been … Read more
Driven by experts, led by science
Integrated CDMO services
By Development Stage
Development Platforms
Route of delivery
About Us
Our Approach
Events
Resources
Policies
Trent Gateway, Technology Drive, Beeston, Nottingham, NG9 1LA, UK. Phone: +44 (0) 115 855 7050 Email: contact@upperton.com
Copyright © 2025 Upperton Limited. Registration number: 03833301. Registered office address: Albert Einstein Centre, Nottingham Science Park, Nottingham, NG7 2TN. Registered in England. All rights reserved.
Speak with our team of experts and set up a discovery call to discuss your project in more detail.